| |
| |
|
| Insider
Information: |
Woiwode Thomas |
| Relationship: |
Director, 10% Owner |
| City: |
Menlo Park |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
4,055,448 |
|
|
Indirect Shares
|
9,845,102 |
|
|
| Direct
Value |
$5,675,411 |
|
|
|
Indirect Value
|
$42,831,608 |
|
|
| Total
Shares |
13,900,550 |
|
|
| Total
Value |
$48,507,019 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -14.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Adverum Biotechnologies, Inc |
ADVM |
Director |
2020-12-14 |
18,822 |
2016-05-11 |
0 |
Premium* |
|
|
Audentes Therapeutics, Inc. |
BOLD |
Director |
2016-07-25 |
0 |
2016-07-25 |
11,308 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
Director |
2018-05-15 |
5,629 |
2018-05-15 |
640,014 |
Premium* |
|
|
Gritstone Oncology, Inc. |
GRTS |
Director |
2021-08-25 |
128 |
2021-08-25 |
3,102,929 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
Director, 10% Owner |
2020-03-03 |
4,026,417 |
2020-03-03 |
933,352 |
Premium* |
|
|
Aligos Therapeutics, Inc. |
ALGS |
Director |
2021-06-11 |
4,452 |
2021-06-11 |
862,444 |
Premium* |
|
|
Tempest Therapeutics, Inc |
TPST |
Director, 10% Owner |
2021-06-25 |
0 |
2022-04-29 |
4,295,055 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TPST |
Tempest Therapeutics, Inc |
Director |
– • • |
2022-04-29 |
4 |
B |
$2.36 |
$5,000,000 |
I/I |
2,118,644 |
2,118,644 |
2.25 |
- |
|
| GRTS |
Gritstone Oncology, Inc. |
Director |
– • – |
2021-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
128 |
128 |
0 |
- |
|
| GRTS |
Gritstone Oncology, Inc. |
Director |
– • – |
2021-08-25 |
4 |
AS |
$0.00 |
$0 |
I/I |
(458,024) |
0 |
0 |
% |
|
| GRTS |
Gritstone Oncology, Inc. |
Director |
– • – |
2021-08-25 |
4 |
A |
$0.00 |
$0 |
I/I |
13,280 |
6,612 |
0 |
- |
|
| TPST |
Tempest Therapeutics, Inc |
|
• • • |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,176,411 |
7,377 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
I/I |
18,102 |
8,383 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2021-06-11 |
4 |
AS |
$0.00 |
$0 |
I/I |
(504,081) |
0 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,226 |
4,452 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,226 |
2,226 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2021-04-26 |
4 |
AS |
$0.00 |
$0 |
I/I |
(504,084) |
0 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
18,105 |
8,385 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Director |
– • – |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
12,783 |
18,822 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2020-10-20 |
4 |
A |
$0.00 |
$0 |
I/I |
3,092,339 |
662,444 |
0 |
- |
|
| ALGS |
Aligos Therapeutics, Inc. |
Director |
– • – |
2020-10-20 |
4 |
B |
$15.00 |
$3,000,000 |
I/I |
200,000 |
862,444 |
2.1 |
- |
|
| PASG |
Passage Bio, Inc. |
Director |
– • • |
2020-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
4,734,769 |
708,352 |
0 |
- |
|
| PASG |
Passage Bio, Inc. |
Director |
– • • |
2020-03-03 |
4 |
B |
$18.00 |
$4,050,000 |
I/I |
225,000 |
933,352 |
2.25 |
% |
|
| PASG |
Passage Bio, Inc. |
Director |
– • • |
2020-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
708,352 |
708,352 |
0 |
- |
|
| PASG |
Passage Bio, Inc. |
Director |
– • • |
2020-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,026,417 |
4,026,417 |
0 |
- |
|
| GRTS |
Gritstone Oncology, Inc. |
Director |
– • • |
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,102,929 |
3,102,929 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-05-15 |
4 |
S |
$57.97 |
$2,551,440 |
I/I |
(44,000) |
640,014 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-05-08 |
4 |
AS |
$51.45 |
$85,047 |
D/D |
(1,653) |
5,629 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-05-07 |
4 |
AS |
$50.31 |
$6,030,826 |
I/I |
(119,709) |
90,730 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-30 |
4 |
AS |
$50.26 |
$1,537,138 |
I/I |
(30,566) |
98,736 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-27 |
4 |
AS |
$50.01 |
$582,655 |
I/I |
(11,648) |
100,780 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-26 |
4 |
AS |
$50.11 |
$10,553,782 |
I/I |
(210,610) |
101,559 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
